摘要:
目的 探讨雷替曲塞联合奥沙利铂治疗晚期结直肠癌(CRC)的疗效及对肿瘤坏死因子-α(TNF-α)、白细胞介素-2(IL-2)的影响.方法 选取晚期CRC患者69例为研究对象,随机分为治疗组35例和对照组34例,治疗组给予雷替曲塞联合奥沙利铂治疗,对照组给予卡培他滨联合奥沙利铂治疗,比较2组近远期疗效及治疗前和治疗3周期后TNF-α、IL-2水平,并记录治疗期间毒副反应的发生情况.结果 治疗组有效率、疾病控制率均略高于对照组(P＞0.05);2组疾病进展时间(TTP)、中位生存期(0S)比较无显著差异(P＞0.05);治疗3周期后,2组TNF-α、IL-2水平均较治疗前明显升高(P＜0.01),且治疗组升高幅度更为显著(P＜0.01);治疗组腹泻、恶心呕吐、中性粒细胞减少发生率显著低于对照组,转氨酶升高显著高于对照组(P＜0.05).结论 雷替曲塞联合奥沙利铂与卡培他滨联合奥沙利铂治疗晚期CRC疗效相近,但雷替曲塞联合奥沙利铂毒副反应轻微.
Abstract:
Objective To explore the clinical efficacy of raltitrexed combined with oxaliplatin in the treatment of patients with advanced colorectal cancer (CRC) and its influence on tumor necrosis factor-α (TNF-α) and interleukin-2 (IL-2).Methods A total of 69 patients with advanced CRC were selected and randomly divided into treatment group (n =35) and control group (n =34).Treatment group was treated with raltitrexed combined with oxaliplatin,while control group was treated with capecitabine combined with oxaliplatin.Short-and long-term clinical efficacy as well as the changes of levels of TNF-α and IL-2 before and 3 weeks after treatment were compared,and the occurrence rates of toxic and adverse reactions were recorded during treatment.Results Treatment group was slightly higher than control group in clinical efficacy and disease control rate (P ＞0.05),and there was also no significant difference between two groups in time to progression (TFP)and median overall survival time (OS) (P ＞ 0.05).After treatment for 3 weeks,levels of TNF-α and IL-2 increased in both groups (P ＜ 0.01),which increased more significantly in treatment group than control group (P ＜ 0.01).Treatment group was significantly lower in the rates of diarrhea,nausea and vomiting,and neutropenia,bur was prominently higher in the increase of transaminase than control group (P ＜ 0.05).Conclusion Rahitrexed combined with oxaliplatin has similar clinical efficacy to capecitabine combined with oxaliplatin in the treatment of advanced CRC,but the former is mild in toxic and adverse reactions.
百度学术
下载:
苏公网安备 32100302010246号